- Statera Biopharma ( NASDAQ: STAB ) on Thursday said a hearings panel had granted the company's request for continued listing on Nasdaq.
- The continued listing was "subject to the company's satisfaction of certain interim milestones," STAB said in a statement .
- The company would also have to comply with all criteria needed for continued listing, including the minimum bid price of $1.00 and $2.5M stockholder's equity requirements, by Jan. 31, 2023.
- STAB stock +0.7% to $0.15 after hours.
For further details see:
Statera Biopharma granted continued listing on Nasdaq